Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical Autonomic Research
Published in: Clinical Autonomic Research 3/2018

01-06-2018 | Review

Autonomic nervous system and cancer

Authors: Marta Simó, Xavier Navarro, Victor J. Yuste, Jordi Bruna

Published in: Clinical Autonomic Research | Issue 3/2018

Login to get access

Abstract

The autonomic nervous system (ANS) is the main homeostatic regulatory system of the body. However, this widely distributed neural network can be easily affected by cancer and by the adverse events induced by cancer treatments. In this review, we have classified the ANS complications of cancer into two categories. The first includes direct cancer-related complications, such as primary ANS tumors (pheochromocytoma, paraganglioma or neuroblastoma), as well as autonomic manifestations induced by non-primary ANS tumors (primary brain tumors and metastases). The second comprises indirect ANS complications, which include autonomic features related to cancer therapy (chemotherapy, radiotherapy and/or surgery) and those not related to cancer therapy, such as paraneoplastic autonomic syndromes. We also review the molecular relationship and modulation between the ANS and the cancer cells and their microenvironment.
Literature
1.
Horn JP, Swanson L (2013) The autonomic motor system and the hypothalamus. In: Kandel ER, Schwartz JH, Jesell TM (eds) Principles of neural science, 5th edn. McGraw-Hill Medical, New York, pp 1066–1078
2.
Beissner F, Meissner K, Bär KJ, Napadow V (2013) The autonomic brain: an activation likelihood estimation meta-analysis for central processing of autonomic function. J Neurosci 33:10503–10511PubMedPubMedCentralCrossRef
3.
Cole SW, Nagaraja AS, Lutgendorf SK, Green PA, Sood AK (2015) Sympathetic nervous system regulation of the tumour microenvironment. Nat Rev Cancer 15:563–572PubMedPubMedCentralCrossRef
4.
Gidron Y, Perry H, Glennie M (2005) Does the vagus nerve inform the brain about preclinical tumours and modulate them? Lancet Oncol 6:245–248PubMedCrossRef
5.
Bertorini TE, Perez A (2014) Neurologic complications of disorders of the adrenal glands. Handb Clin Neurol 120:749–771PubMedCrossRef
6.
Tischler AS (2008) Pheochromocytoma and extra-adrenal paraganglioma updates. Arch Pathol Lab Med 132:1272–1284PubMed
7.
Matthay KK, Maris JM, Schleiermacher G, Nakagawara A, Mackall CL, Diller L, Weiss WA (2016) Neuroblastoma. Nat Rev Dis Primers 2:16078PubMedCrossRef
8.
Pacak K, Linehan WM, Eisenhofer G, Walther MM, Goldstein DSl (2001) Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med 134:315–329PubMedCrossRef
9.
10.
Bravo EL, Gifford RW (1984) Current concepts. Pheochromocytoma: diagnosis, localization and management. N Engl J Med 311:1298–1303PubMedCrossRef
11.
Stein PP, Black HRA (1991) A simplified diagnostic approach to pheochromocytoma. A review of the literature and report of one institution’s experience. Medicine (Baltimore) 70:46–66CrossRef
12.
Jadoul M, Leo JR, Berends MJ, Ooms EC, Buurke EJ, Vasen HF, Seelen PJ, Lips CJ (1989) Pheochromocytoma-induced hypertensive encephalopathy revealing MEN-IIa syndrome in a 13-year old boy. Implications for screening procedures and surgery. Horm Metab Res Suppl 21:46–49PubMed
13.
Eclavea A, Gagliardi JA, Jezior J, Burton B, Donahue JP (1997) Phaeochromocytoma with central nervous system manifestations. Australas Radiol 41:373–376PubMedCrossRef
14.
Serter A, Alkan A, Aralasmak A, Kocakoc E (2013) Severe posterior reversible encephalopathy in pheochromocytoma: importance of susceptibility-weighted MRI. Korean J Radiol 14:849–853PubMedPubMedCentralCrossRef
15.
16.
Kassim TA, Clarke DD, Mai VQ, Clyde PW, Mohamed Shakir KM (2008) Catecholamine-induced cardiomyopathy. Endocr Pract 14:1137–1149
17.
Ruggeri RM, Ferraù F, Campennì A, Simone A, Barresi V, Giuffrè G, Tuccari G, Baldari S, Trimarchi F (2009) Immunohistochemical localization and functional characterization of somatostatin receptor subtypes in a corticotropin releasing hormone-secreting adrenal phaeochromocytoma: review of the literature and report of a case. Eur J Histochem 53:1–6PubMedCrossRef
18.
Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, Naruse M, Pacak K, Young WF (2014) Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99:1915–1942PubMedCrossRef
19.
Timmers HJ, Chen CC, Carrasquillo JA, Whatley M, Ling A, Eisenhofer G, King KS, Rao JU, Wesley RA, Adams KT, Pacak K (2012) Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography. J Natl Cancer Inst 104:700–708PubMedPubMedCentralCrossRef
20.
Grossrubatscher E, Dalino P, Vignati F, Gambacorta M, Pugliese R, Boniardi M, Rossetti O, Marocchi A, Bertuzzi M, Loli P (2006) The role of chromogranin A in the management of patients with phaeochromocytoma. Clin Endocrinol (Oxf) 65:287–293CrossRef
21.
Ellison DA, Parham DM (2001) Tumors of the autonomic nervous system. Am J Clin Pathol 115(Suppl):S46–S55PubMed
22.
Linnoila RI, Keiser HR, Steinberg SM, Lack EE (1990) Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features. Hum Pathol 21:1168–1180PubMedCrossRef
23.
Lloyd RV, Sisson JC, Shapiro B, Verhofstad AA (1986) Immunohistochemical localization of epinephrine, norepinephrine, catecholamine-synthesizing enzymes, and chromogranin in neuroendocrine cells and tumors. Am J Pathol 125:45–54PubMedPubMedCentral
24.
Chen H, Sippel RS, O’Dorisio MS, Vinik AI, Lloyd RV, Pacak K (2010) The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas 39:775–783PubMedPubMedCentralCrossRef
25.
Bryant J, Farmer J, Kessler LJ, Townsend RR, Nathanson KL (2003) Pheochromocytoma: the expanding genetic differential diagnosis. J Natl Cancer Inst 95:1196–1204PubMedCrossRef
26.
Burnichon N, Brière JJ, Libé R, Vescovo L, Rivière J, Tissier F, Jouanno E, Jeunemaitre X, Bénit P, Tzagoloff A, Rustin P, Bertherat J, Favier J, Gimenez-Roqueplo AP (2010) SDHA is a tumor suppressor gene causing paraganglioma. Hum Mol Genet 19:3011–3020PubMedPubMedCentralCrossRef
27.
Fishbein L, Merrill S, Fraker DL, Cohen DL, Nathanson KL (2013) Inherited mutations in pheochromocytoma and paraganglioma: why all patients should be offered genetic testing. Ann Surg Oncol 20:1444–1450PubMedPubMedCentralCrossRef
28.
Unger P, Hoffman K, Pertsemlidis D, Thung S, Wolfe D, Kaneko M (1991) S100 protein-positive sustentacular cells in malignant and locally aggressive adrenal pheochromocytomas. Arch Pathol Lab Med 115:484–487PubMed
29.
Chrisoulidou A, Kaltsas G, Ilias I, Grossman AB (2007) The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer 14:569–585PubMedCrossRef
30.
Vo KT, Matthay KK, Neuhaus J, London WB, Hero B, Ambros PF, Nakagawara A, Miniati D, Wheeler K, Pearson AD, Cohn SL, DuBois SG (2014) Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the International Neuroblastoma Risk Group Project. J Clin Oncol 32:3169–3176PubMedPubMedCentralCrossRef
31.
DuBois SG, Kalika Y, Lukens JN, Brodeur GM, Seeger RC, Atkinson JB, Haase GM, Black CT, Perez C, Shimada H, Gerbing R, Stram DO, Matthay KK (1999) Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol 21:181–189PubMedCrossRef
32.
Hero B, Schleiermacher G (2013) Update on pediatric opsoclonus myoclonus syndrome. Neuropediatrics 44:324–329PubMedCrossRef
33.
Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B (1999) The international neuroblastoma pathology classification (the Shimada system). Cancer 86:364–372PubMedCrossRef
34.
Park JR, Bagatell R, London WB, Maris JM, Cohn SL, Mattay KK, Hogarty M (2013) Children’s Oncology Group’s 2013 blueprint for research: neuroblastoma. Pediatr Blood Cancer 60:985–993PubMedCrossRef
35.
Glantz MJ, Cole BF, Forsyth PA, Recht LD, Wen PY, Chamberlain MC, Grossman SA, Cairncross JG (2000) Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 54:1886–1893PubMedCrossRef
36.
Cayuela N, Simó M, Majós C, Rifà-Ros X, Gállego Pérez-Larraya J, Ripollés P, Vidal N, Miró J, Gil F, Gil-Gil M, Plans G, Graus F, Bruna J (2018) Seizure-susceptible brain regions in glioblastoma: identification of patients at risk. Eur J Neurol 25:387–394PubMedCrossRef
37.
Moseley B, Bateman L, Millichap JJ, Wirrell E, Panayiotopoulos CP (2013) Autonomic epileptic seizures, autonomic effects of seizures, and SUDEP. Epilepsy Behav 26:375–385PubMedCrossRef
38.
Romigi A, Albanese M, Placidi F, Izzi F, Mercuri NB, Marchi A, Liguori C, Campagna N, Duggento A, Canichella A, Ricciardo Rizzo G, Guerrisi M, Marciani MG, Toschi N (2016) Heart rate variability in untreated newly diagnosed temporal lobe epilepsy: evidence for ictal sympathetic dysregulation. Epilepsia 57:418–426PubMedCrossRef
39.
Panayiotopoulos CP (2007) Generalised tonic–clonic seizures. In: Panayiotopoulos CP (ed) A clinical guide to epileptic syndromes and their treatment, 2nd edn. Springer, London, pp 27–38
40.
Panayiotopoulos CP (2007) Symptomatic and cryptogenic (probably symptomatic) focal epilepsies. In: Panayiotopoulos CP (ed) A clinical guide to epileptic syndromes and their treatment, 2nd edn. Springer, London, pp 375–436
41.
42.
Grisold W, Briani C, Vass A (2013) Malignant cell infiltration in the peripheral nervous system. Handb Clin Neurol 115:685–712PubMedCrossRef
43.
Pancoast HK (1932) Superior pulmonary sulcus tumor: tumor characterized by pain, Horner’s syndrome, destruction of bone and atrophy of hand muscles. JAMA 99:1391–1396CrossRef
44.
Kori SH, Foley KM, Posner JB (1981) Brachial plexus lesions in patients with cancer: 100 cases. Neurology 31:45–50PubMedCrossRef
45.
Ganju A, Roosen N, Kline DG, Tiel RL (2001) Outcomes in a consecutive series of 111 surgically treated plexus tumours: a review of the experience at the Louisiana State University health sciences center. J Neurosurg 95:51–60PubMedCrossRef
46.
Ferrante MA (2004) Brachial plexopathies: classification, causes, and consequences. Muscle Nerve 30:547–568PubMedCrossRef
47.
Ku A, Lachmann E, Tunkel R, Nagler W (1996) Upper limb reflex sympathetic dystrophy associated with occult malignancy. Arch Phys Med Rehabil 77:726–728PubMedCrossRef
48.
Jaeckle KA, Young DF, Foley KM (1985) The natural history of lumbosacral plexopathy in cancer. Neurology 35:8–15PubMedCrossRef
49.
Jaeckle KA (2004) Neurological manifestations of neoplastic and radiation-induced plexopathies. Semin Neurol 24:385–393PubMedCrossRef
50.
Dalmau J, Graus F, Marco M (1989) ‘Hot and dry foot’ as initial manifestation of neoplastic lumbosacral plexopathy. Neurology 39:871–872PubMedCrossRef
51.
Argyriou AA, Bruna J, Marmiroli P, Cavaletti G (2012) Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol 82:51–77CrossRef
52.
Krarup-Hansen A, Helweg-Larsen S, Schmalbruch H, Rørth M, Krarup C (2007) Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies. Brain 130:1076–1088PubMedCrossRef
53.
Velasco R, Petit J, Clapés V, Verdú E, Navarro X, Bruna J (2010) Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients. J Peripher Nerv Syst 15:17–25PubMedCrossRef
54.
Haim N, Epelbaum R, Ben-Shahar M, Yarnitsky D, Simri W, Robinson E (1994) Full dose vincristine (without 2-mg dose limit) in the treatment of lymphomas. Cancer 73:2515–2519PubMedCrossRef
55.
Kornblith AB, Anderson J, Cella DF, Tross S, Zuckerman E, Cherin E, Henderson ES, Canellos GP, Kosty MP, Cooper MR (1992) Comparison of psychosocial adaptation and sexual function of survivors of advanced Hodgkin disease treated by MOPP ABVD, or MOPP alternating with ABVD. Cancer 70:2508–2516PubMedCrossRef
56.
Rowinsky EK, McGuire WP, Guarnieri T, Fisherman JS, Christian MC, Donehower RC (1991) Cardiac disturbances during the administration of taxol. J Clin Oncol 9:1704–1712PubMedCrossRef
57.
Meinardi MT, Van Veldhuisen DJ, Gietema JA, Dolsma WV, Boomsma F, Van Den Berg MP, Van Der Graaf WTA (2001) Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol 19:2746–2753PubMedCrossRef
58.
Tjeerdsma G, Meinardi MT, van Der Graaf WT, van Den Berg MP, Mulder NH, Crijns HJ, de Vries EG, van Veldhuisen DJ (1999) Early detection of anthracycline induced cardiotoxicity in asymptomatic patients with normal left ventricular systolic function: autonomic versus echocardiographic variables. Heart 81:419–423PubMedPubMedCentralCrossRef
59.
Arab C, Dias DP, Barbosa RT, Carvalho TD, Valenti VE, Crocetta TB, Ferreira M, Abreu LC, Ferreira C (2016) Heart rate variability measure in breast cancer patients and survivors: a systematic review. Psychoneuroendocrinology 68:57–68PubMedCrossRef
60.
Davagnanam I, Fraser CI, Miszkiel K, Daniel CS, Plant GT (2013) Adult Horner’s syndrome: a combined clinical, pharmacological, and imaging algorithm. Eye 27:271–298
61.
Bhandare N, Moiseenko V, Song WY, Morris CG, Bhatti MT, Mendenhall WM (2012) Severe dry eye syndrome after radiotherapy for head-and-neck tumors. Int J Radiat Oncol Biol Phys 82:1501–1508PubMedCrossRef
62.
Pinna R, Campus G, Cumbo E, Mura I, Milia E (2015) Xerostomia induced by radiotherapy: an overview of the physiopathology, clinical evidence, and management of the oral damage. Ther Clin Risk Manag 11:171–188PubMedPubMedCentralCrossRef
63.
Magliulo G, Cordeschi S, Sepe C, de Vincentiis M (1998) Taste and lacrimation after acoustic neuroma surgery. Rev Laryngol Otol Rhinol 119:167–170
64.
65.
Huang CC, Huang TL, Hsu HC, Chen HC, Lin HC, Chien CY, Fang FM, Chang HW, Tsai NW, Chang WN, Chen SF, Lin TK, Tan TY, Chang CR, Wang HC, Lin WC, Lu CH (2013) Long-term effects of neck irradiation on cardiovascular autonomic function: a study in nasopharyngeal carcinoma patients after radiotherapy. Muscle Nerve 47:344–350PubMedCrossRef
66.
Perino LE, Schuffler MD, Mehta SJ, Everson GT (1986) Radiation-induced intestinal pseudoobstruction. Gastroenterology 91:994–998PubMedCrossRef
67.
Van Duijvendijk P, Slors JF, Taat CW, van Tets WF, van Tienhoven G, Obertop H, Boeckxstaens GE (2002) Prospective evaluation of anorectal function after total mesorectal excision for rectal carcinoma with or without preoperative radiotherapy. Am J Gastroenterol 97:2282–2289PubMedCrossRef
68.
Krol R, Smeenk RJ, van Lin ENJT, Yeoh EEK, Hopman WPM (2014) Systematic review: anal and rectal changes after radiotherapy for prostate cancer. Int J Colorectal Dis 29:273–283PubMedCrossRef
69.
Havenga K, Maas CP, Deruiter MC, Welvaart K, Trimbos JB (2000) Avoiding long-term disturbance to bladder and sexual function in pelvic surgery, particularly with rectal cancer. Semin Surg Oncol 18:235–243PubMedCrossRef
70.
Sharabi Y, Dendi R, Holmes C, Goldstein DS (2003) Baroreflex failure as a late sequela of neck irradiation. Hypertension 42:110–116PubMedCrossRef
71.
Timmers HJ, Karemaker JM, Lenders JW, Wieling W (1999) Baroreflex failure following radiation therapy for nasopharyngeal carcinoma. Clin Auton Res 9:317–324PubMedCrossRef
72.
Shah-Becker S, Pennock M, Sinoway L, Goldenberg D, Goyal N (2017) Baroreceptor reflex failure: review of the literature and the potential impact on patients with head and neck cancer. Head Neck 39:2135–2141PubMedCrossRef
73.
Goyal M, Shukla P, Gupta D, Bisht S, Verma NS, Tiwari S, Bhatt ML (2017) Cardiovascular sequel of neck irradiation in head and neck cancer patients. Int J Radiat Biol 93:711–716PubMedCrossRef
74.
Darnell RB, Posner JB (2011) Paraneoplastic syndromes. In: Darnell RB, Posner JB (eds) Paraneoplastic syndromes, 1st edn. Oxford University Press, Oxford, pp 3–83
75.
Dalmau J, Graus F, Rosenblum MK, Posner JB (1992) Anti-Hu-associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine (Baltimore) 71:59–72CrossRef
76.
Dalmau J, Graus F, Villarejo A, Posner JB, Blumenthal D, Thiessen B, Saiz A, Meneses P, Rosenfeld MR (2004) Clinical analysis of anti-Ma2-associated encephalitis. Brain 127:1831–1844PubMedCrossRef
77.
Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, Dessain SK, Rosenfeld MR, Balice-Gordon R, Lynch DR (2008) Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 7:1091–1098PubMedPubMedCentralCrossRef
78.
Graus F, Keime-Guibert F, Reñe R, Benyahia B, Ribalta T, Ascaso C, Escaramis G, Delattre JY (2001) Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 124:1138–1148PubMedCrossRef
79.
Gultekin SH, Rosenfeld MR, Voltz R, Eichen J, Posner JB, Dalmau J (2000) Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain 123:1481–1494PubMedCrossRef
80.
Hart IK, Maddison P, Newsom-Davis J, Vincent A, Mills KR (2002) Phenotypic variants of autoimmune peripheral nerve hyperexcitability. Brain 125:1887–1895PubMedCrossRef
81.
Höftberger R, Titulaer MJ, Sabater L, Dome B, Rózsás A, Hegedus B, Hoda MA, Laszlo V, Ankersmit HJ, Harms L, Boyero S, de Felipe A, Saiz A, Dalmau J, Graus F (2013) Encephalitis and GABAB receptor antibodies: novel findings in a new case series of 20 patients. Neurology 81:1500–1506PubMedPubMedCentralCrossRef
82.
Höftberger R, van Sonderen A, Leypoldt F, Houghton D, Geschwind M, Gelfand J, Paredes M, Sabater L, Saiz A, Titulaer MJ, Graus F, Dalmau J (2015) Encephalitis and AMPA receptor antibodies: novel findings in a case series of 22 patients. Neurology 84:2403–2412PubMedPubMedCentralCrossRef
83.
Mason WP, Graus F, Lang B, Honnorat J, Delattre JY, Valldeoriola F, Antoine JC, Rosenblum MK, Rosenfeld MR, Newsom-Davis J, Posner JB, Dalmau J (1997) Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert–Eaton myasthenic syndrome. Brain 120:1279–1300PubMedCrossRef
84.
Petit-Pedrol M, Armangue T, Peng X, Bataller L, Cellucci T, Davis R, McCracken L, Martinez-Hernandez E, Mason WP, Kruer MC, Ritacco DG, Grisold W, Meaney BF, Alcalá C, Sillevis-Smitt P, Titulaer MJ, Balice-Gordon R, Graus F, Dalmau J (2014) Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. Lancet Neurol 13:276–286PubMedPubMedCentralCrossRef
85.
Saiz A, Bruna J, Stourac P, Vigliani MC, Giometto B, Grisold W, Honnorat J, Psimaras D, Voltz R, Graus F (2009) Anti-Hu-associated brainstem encephalitis. J Neurol Neurosurg Psychiatry 80:404–407
86.
Yu Z, Kryzer TJ, Griesmann GE, Kim K, Benarroch EE, Lennon VA (2001) CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 49:146–154PubMedCrossRef
87.
88.
Wirtz PW, Smallegange TM, Wintzen AR, Verschuuren JJ (2002) Differences in clinical features between the Lambert–Eaton myasthenic syndrome with and without cancer: an analysis of 227 published cases. Clin Neurol Neurosurg 104(4):359–363PubMedCrossRef
89.
Wabbels BK, Elflein H, Lorenz B, Kolling G (2004) Bilateral tonic pupils with evidence of anti-Hu antibodies as a paraneoplastic manifestation of small cell lung cancer. Ophthalmologica 218:141–143PubMedCrossRef
90.
Lladó A, Mannucci P, Carpentier AF, Paris S, Blanco Y, Saiz A, Delattre JY, Graus F (2004) Value of Hu antibody determinations in the follow-up of paraneoplastic neurologic syndromes. Neurology 63:1947–1949PubMedCrossRef
91.
Walsh D, Nelson KA (2002) Autonomic nervous system dysfunction in advanced cancer. Support Care Cancer 10:523–528PubMedCrossRef
92.
Miller AH, Ancoli-Israel S, Bower JE, Capuron L, Irwin MR (2008) Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. J Clin Oncol 26:971–982PubMedPubMedCentralCrossRef
93.
Lakoski SG, Jones LW, Krone RJ, Stein PK, Scott JM (2015) Autonomic dysfunction in early breast cancer: incidence, clinical importance, and underlying mechanisms. Am Heart J 170:231–241PubMedPubMedCentralCrossRef
94.
Ondicova K, Mravec B (2010) Role of nervous system in cancer aetiopathogenesis. Lancet Oncol 1:596–601CrossRef
95.
Mancino M, Ametller E, Gascón P, Almendro V (2011) The neuronal influence on tumor progression. Biochim Biophys Acta 1816:105–118PubMed
96.
Jobling P, Pundavela J, Oliveira SM, Roselli S, Walker MM, Hondermarck H (2015) Nerve-cancer cell cross-talk: a novel promoter of tumor progression. Cancer Res 1(75):1777–1781CrossRef
97.
Cole SW, Sood AK (2012) Molecular pathways: beta-adrenergic signaling in cancer. Clin Cancer Res 18:1201–1206PubMedCrossRef
98.
Tang J, Li Z, Lu L, Cho CH (2013) β-Adrenergic system, a backstage manipulator regulating tumour progression and drug target in cancer therapy. Semin Cancer Biol 23:533–542PubMedCrossRef
99.
Lu L, Chen Y, Zhu Y (2017) The molecular basis of targeting PFKFB3 as a therapeutic strategy against cancer. Oncotarget 8:62793–62802PubMedPubMedCentral
100.
Poulsen H, Morth P, Egebjerg J, Nissen P (2010) Phosphorylation of the Na+ , K+-ATPase and the H+, K+-ATPase. FEBS Lett 584:2589–2595PubMedCrossRef
101.
Romero-Garcia S, Moreno-Altamirano MM, Prado-Garcia H, Sánchez-García FJ (2016) Lactate contribution to the tumor microenvironment: mechanisms, effects on immune cells and therapeutic relevance. Front Immunol 7:52PubMedPubMedCentralCrossRef
102.
Spindel ER (2012) Muscarinic receptor agonists and antagonists: effects on cancer. Handb Exp Pharmacol 208:451–468CrossRef
103.
Schuller HM (2009) Is cancer triggered by altered signalling of nicotinic acetylcholine receptors? Nat Rev Cancer 9:195–205PubMedCrossRef
104.
Shah N, Khurana S, Cheng K, Raufman JP (2009) Muscarinic receptors and ligands in cancer. Am J Physiol Cell Physiol 296:C221–C232PubMedCrossRef
105.
Campoy FJ, Vidal CJ, Muñoz-Delgado E, Montenegro MF, Cabezas-Herrera J, Nieto-Cerón S (2016) Cholinergic system and cell proliferation. Chem Biol Interact 259:257–265PubMedCrossRef
106.
Zhang XJ, Yang L, Zhao Q, Caen JP, He HY, Jin QH, Guo LH, Alemany M, Zhang LY, Shi YF (2002) Induction of acetylcholinesterase expression during apoptosis in various cell types. Cell Death Differ 9:790–800PubMedCrossRef
107.
108.
109.
110.
Sánchez-Osuna M, Martínez-Escardó L, Granados-Colomina C, Martínez-Soler F, Pascual-Guiral S, Iglesias-Guimarais V, Velasco R, Plans G, Vidal N, Tortosa A, Barcia C, Bruna J, Yuste VJ (2016) An intrinsic DFF40/CAD endonuclease deficiency impairs oligonucleosomal DNA hydrolysis during caspase-dependent cell death: a common trait in human glioblastoma cells. Neuro Oncol 18:950–961PubMedPubMedCentralCrossRef
Metadata
Title
Autonomic nervous system and cancer
Authors
Marta Simó
Xavier Navarro
Victor J. Yuste
Jordi Bruna
Publication date
01-06-2018
Publisher
Springer Berlin Heidelberg
Published in
Clinical Autonomic Research / Issue 3/2018
Print ISSN: 0959-9851
Electronic ISSN: 1619-1560
DOI
https://doi.org/10.1007/s10286-018-0523-1

Other articles of this Issue 3/2018

Clinical Autonomic Research 3/2018 Go to the issue

Editorial

Increased cardiac sympathetic activity: Cause or compensation in vasovagal syncope?

Review

Roles of catechol neurochemistry in autonomic function testing

Review

Neural pathways involved in infection-induced inflammation: recent insights and clinical implications

Review

The pathophysiology of the trigeminal autonomic cephalalgias, with clinical implications

Research Article

Modeling human orthostatic responses on the Moon and on Mars

Editorial

Extraterrestrial autonomic function